Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway

Peng Xu1 · Handong Wang1 · Hao Pan1 · Jiakai Chen2 · Chulei Deng3

Received: 16 August 2021 / Accepted: 22 November 2021 / Published online: 8 January 2022
© The Author(s) 2022

Abstract
Purpose Anlotinib protects against carcinogenesis through the induction of autophagy and apoptosis. The current study evaluated the role and molecular mechanisms of anlotinib in glioblastoma, and the effects of anlotinib in combination with temozolomide (TMZ).

Methods Cell Counting Kit-8 and colony-forming assays were used to evaluate cell viability. Cell migration and invasion were assessed by wound-healing, Transwell migration, and Matrigel invasion assays. Cellular apoptosis and cell cycle analysis were determined by flow cytometry. Angiogenesis was assessed using human umbilical vein endothelial cells (HUVECs). Vascular endothelial growth factor A (VEGFA) was measured by enzyme-linked immunosorbent assay. Protein expression was determined by western blotting or immunofluorescence staining. The in vivo anti-glioblastoma effect was assessed with live imaging of tumor xenografts in nude mice.

Results Anlotinib restricted the proliferation, migration, and invasion of glioblastoma cells in a dose-dependent manner. Tumor supernatant from glioblastoma cells treated with anlotinib inhibited angiogenesis in HUVECs. Anlotinib induced autophagy in glioblastoma cells by increasing Beclin-1 and microtubule-associated protein 1 light chain 3B (LC3B) levels. Mechanistically, anlotinib inhibited the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/VEGFA signaling pathway. STAT3 inhibition by S3I-201 decreased VEGFA and suppressed cellular proliferation and movement. TMZ enhanced the anti-glioblastoma ability of anlotinib. Finally, anlotinib inhibited tumor growth and JAK2/STAT3/VEGFA signaling in xenografts.

Conclusion Anlotinib exerts anti-glioblastoma activity possibly through the JAK2/STAT3/VEGFA signaling pathway. TMZ potentiated the anti-glioblastoma effect of anlotinib via the same signaling pathway, indicating the potential application of anlotinib as a treatment option for glioblastoma.

Keywords Anlotinib · Glioblastoma · JAK2/STAT3/VEGFA signaling pathway · Proliferation · Migration · Invasion

1 Department of Neurosurgery, Jinling Hospital, School of Medicine, Southeast University, 305 East Zhongshan Road, Nanjing 210002, Jiangsu, China
2 Department of Neurosurgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu, China
3 Department of Neurosurgery, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing 210002, China
Introduction

Gliomas are the most common primary intracranial tumor. More than half of all gliomas are malignant in adults, and comprise more than 80% of malignant tumors in the central nervous system. Glioblastoma multiforme (GBM) accounts for more than 50% of total gliomas [1]. The standard treatment option of GBM is surgery accompanied by chemotherapy and radiotherapy. However, the poor prognosis of patients with GBM is commonly attributed to its high rates of malignancy and its insensitivity to chemoradiotherapy. Despite therapeutic advances including accurate surgical techniques and additional chemotherapeutic options, the median survival from the time of diagnosis is only 12–15 months [2], and the 5-year survival rate is below 5% [3]. According to the currently accepted standard protocols, temozolomide (TMZ) is the first-line chemotherapeutic agent for GBM and increases survival to approximately 14 months [4]. Therefore, new strategies for the treatment of GBM are urgently required.

Angiogenesis has a crucial role in tumorigenesis and metastasis is an important component of various tumor types that needs to be understood for proper treatment. Resistance to classical treatment can be due to the formation of abnormal vasculature and local tumor cell metastasis [5]. Vascular endothelial growth factor (VEGF), and its high affinity receptor (VEGFR), dramatically enhances the capacity of angiogenesis. Thus, VEGF overexpression often results in worse clinical outcomes for glioma patients [6, 7]. Indeed, the concentration of VEGFA (one of five members in the VEGF protein family) is increased in higher grade glioma tissue [8]. Anti-angiogenic therapy is one of the most promising approaches to glioma treatment; however, there currently is no efficacious therapeutic anti-angiogenesis drug for clinical use to treat gliomas.

Anlotinib is a novel multi-targeted tyrosine kinase inhibitor that has shown significant and positive results in a variety of tumors [9], and can target VEGFR2, fibroblast growth factor receptor 1, platelet-derived growth factor receptor β, and the stem cell factor receptor. Anlotinib may inhibit endothelial cell migration and angiogenesis via extracellular signal-regulated kinase (ERK) signaling [10]. Recently, the anticancer function of anlotinib has been highlighted in lung cancer [11, 12], liver cancer [13], and osteosarcoma [14]. Although the inhibitory effects of anlotinib on U87 (human primary glioblastoma cell line) cellular proliferation have been previously reported [15], the underlying molecular mechanisms of anlotinib in glioblastoma and its effects in combination with TMZ need additional research to enhance preclinical understanding prior to clinical studies. Importantly, the potential mechanisms of anlotinib underlying the anti-GBM effects and its effects on A172 and U251 cells (human glioblastoma cell lines) remain unclear. In addition, the mechanism of the synergistic effect between anlotinib and TMZ is not clear.

Accumulating evidence has suggested that the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway is important during tumorigenesis and angiogenesis [11, 16, 17]. Hence, the current study evaluated the relationship between the JAK2/STAT3 pathway and anti-angiogenic effects, with a focus on VEGFA expression. It was also demonstrated that combined with TMZ, the therapeutic efficacy of anlotinib was enhanced, in terms of its anti-proliferative, anti-apoptotic, and anti-angiogenic effects.

Materials and methods

Cell culture

A172, U87, and U251 human glioblastoma cell lines were purchased from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Human umbilical vein endothelial cells (HUVECs) were purchased from Jin Yuan Organism (Shanghai, China). The human glioblastoma cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific) and 100 units/mL penicillin/streptomycin (HyClone, GE Healthcare Life Sciences, Logan, UT, USA) at 37 °C in a humidified atmosphere of 95% air and 5% CO₂. Then, HUVECs were cultured in Endothelial Cell Medium (ECM; ScienCell, Carlsbad, CA, USA) with 5% fetal bovine serum (FBS; ScienCell, Carlsbad, CA, USA) and 1% endothelial cell growth supplement (ECGS; ScienCell, Carlsbad, CA, USA) and 1% antibiotic solution (P/S; ScienCell, Carlsbad, CA, USA) at 37 °C in a humidified atmosphere of 95% air and 5% CO₂. Media was changed every 48–72 h. For each passage, cells were washed twice with phosphate-buffered saline (PBS; HyClone), then incubated at 37 °C with 0.25% trypsin–EDTA (Sigma-Aldrich Co.) to lift the cells. For experiments, cell monolayers were grown to approximately 70% confluence in culture medium prior to the initiation of experimental conditions.

Reagents and antibodies

Anlotinib, TMZ, S3I-201, and 3-methyl adenine (3-MA) were obtained from Selleckchem (Houston, TX, USA). Anlotinib was prepared as a 10 mM stock solution in dimethyl sulfoxide (DMSO). TMZ was prepared as a 50 mM stock solution in DMSO. Antibodies against phosphorylated (p)-JAK2, STAT3, p-STAT3, microtubule-associated protein 1 light chain 3B (LC3B), Beclin-1, and caspase-3, as well
as goat anti-rabbit and anti-mouse immunoglobulin G (IgG; H&L) secondary antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies against B cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (BAX) were purchased from Santa Cruz Biotechnology (Delaware, CA, USA). The anti-VEGFA antibody was from Abcam (Cambridge, MA, USA). Antibodies against B cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (BAX) were purchased from Santa Cruz Biotechnology (Delaware, CA, USA). The anti-VEGFA antibody was from Abcam (Cambridge, MA, USA). Antibodies against cyclin A2, cyclin D1, high mobility group box protein 1 (HMGB1), and matrix-metalloprotease 2 (MMP2) were obtained from ProteinTech Group Inc. (Chicago, IL, USA). The β-actin antibody was purchased from Bioworld Technology (Louis, MN, USA). The anti-Ki-67 antibody (Absin; Shanghai, China) was used for immunohistochemistry (IHC). Horse-radish peroxidase (HRP)-conjugated goat anti-rabbit IgG and FITC-conjugated anti-rabbit IgG antibodies were from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA).

**Cell viability assay**

The Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) was used to determine cell viability following the manufacturer’s instruction. A172, U87, and U251 cells were seeded in 96-well plates (3 × 10^3 cells/well) for 24 h. Anlotinib was diluted in DMEM to achieve final treatment concentrations of 0, 1.25, 2.5, 5, 10, and 20 µM for either 24, 48, or 72 h. In combination drug studies, TMZ (100 µM) and anlotinib (2 µM) were added to the media for 48 h. Next, 100 µL of 10% CCK-8 solution diluted in DMEM was added into each well. After incubating at 37 °C for 2 h, the plates were analyzed with the Bio-Rad enzyme-linked immunosorbent assay (ELISA) microplate reader at 450 nm (OD450). Cell viability was determined using the following formula: cell viability = (OD450 of treated groups/OD450 of control group) × 100%.

**Colony-forming assay**

A172, U251, and U87 glioblastoma cells were seeded into six-well plates (1,000 cells/well) and treated with anlotinib (0, 2, and 4 µM). The media and treatment were refreshed every 3 days. After incubation at 37 °C for 14 days, the colonies were washed with PBS and fixed with methanol for 20 min. After staining with 0.1% crystal violet (Sigma-Aldrich Co.), the colonies were visualized and quantified.

**Wound-healing assay**

The migration of cells (A172, U87, and U251) was assessed using a standard in vitro wound-healing assay. The cells were grown in normal growth media to 70% confluence in six-well tissue culture plates. Next, the cells were scraped with a 200 µL pipette tip, washed with PBS, and incubated in serum-free media containing anlotinib (0, 2, and 4 µM) at 37 °C for 0 and 24 h. In combination drug studies, U87 and U251 cells were cultured in anlotinib (2 µM) with or without TMZ (100 µM) for 48 h. The changes in wounded areas were observed and imaged using a light microscope (Carl Zeiss Meditec AG, Jena, Germany). The wounded areas from four random fields of view were subsequently measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA) and the percent healing was determined with the following formula: wound healing (%) = (initial scratch area−final scratch area)/initial scratch area × 100%. The results were analyzed using GraphPad Prism 8 software (version 8.0.2; GraphPad Software Inc., La Jolla, CA, USA).

**Migration and invasion assay**

Transwell assays (with or without Matrigel) were used to evaluate the motile and invasive capacities of A172, U87, and U251 cells treated with anlotinib. Transwell assays were performed using an Invasion Chamber (Corning Inc., NY, USA) following the manufacturer’s instructions. Briefly, for the migration assay, cells (2 × 10^5) in 200 µL serum-free DMEM were added to the upper chamber of 6.5 mm Transwells (8.0 µm pore; polycarbonate membrane inserts; Corning Inc.). For the invasion assay, the upper chambers were coated with a matrix of Matrigel (Corning Inc.). With both experimental protocols, the lower chambers contained DMEM with 10% FBS. After an incubation at 37 °C for 16 h, the cells in upper chamber that did not penetrate the membrane were removed. Subsequently, the chambers were fixed with paraformaldehyde for 15 min and stained with 0.1% crystal violet for 10 min. Cells were counted in five random fields of view/insert using a light microscope.

**Flow cytometry**

For cell cycle analysis, A172, U87, and U251 cells were cultured and harvested after treatment, then fixed with 70% ethanol. After propidium iodide (PI; 500 µL) staining, nuclei were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).

For apoptosis analysis, cells were harvested and suspended in 300 µL of binding buffer containing 5 µL of annexin V-FITC (AV; KGA108, KeyGEN, China) and 5 µL of PI (BD Biosciences). After an additional 200 µL of binding buffer was added, the apoptotic cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences).

**Western blot**

Western blot assays were performed as previously described [18]. In brief, A172, U87, and U251 cells were treated with anlotinib (2 µM) and/or S3I-201 (100 µM) for 24 h. In a
separate experiment, U87 and U251 cells were cultured in media containing anlotinib (2 μM) with or without TMZ (100 μM) for 24 h. Cells were harvested, and protein concentrations were determined using the bicinchoninic acid Protein Assay Kit (Beyotime). Equal amounts of protein were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis on 8–12% gels and then transferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). After blocking with 5% non-fat milk for 2 h at room temperature, the membranes were incubated at 4 °C overnight with the appropriate primary antibodies. After washing with tris-buffered saline with Tween 20, membranes were incubated with the corresponding secondary HRP-conjugated antibodies. Finally, protein bands were visualized using enhanced chemiluminescence detection reagents (EMD Millipore) and a chemiluminescence imaging system (Tanon, Shanghai, China).

ELISA and tubular formation assay

VEGFA concentrations in the supernatants from U87 cells were determined using human VEGFA ELISA kits (Jianglai-bio, Shanghai, China) according to the manufacturer’s instructions.

To visualize the micro-vessels, HUVECs were cultured in tumor cell supernatant (without FBS) and seeded onto a 96-well plate (3 × 10⁴ cells/well) coated with 50 μL Matrigel (Corning Incorporated, USA). Then, cells were incubated at 37 °C in 5% CO₂. Six hours after seeding, tubules were photographed using light microscopy and evaluated by Image Pro Plus software.

Immunofluorescence

U87 and U251 cells were seeded onto glass cover slips and allowed to adhere for 12 h. After treatment with anlotinib (4 μM) and an inhibitor of autophagy (3-MA; 5 mM) for 24 h, the cells were fixed with 4% paraformaldehyde for 15 min, then permeabilized with 0.3% Triton X-100 for 10 min. Coverslips were then incubated with the primary antibody against LC3B at 4 °C overnight, and the CY3-conjugated secondary antibody for 1 h at room temperature. The nuclei were stained using 4’,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for 10 min. All images were taken using a ZEISS immunofluorescence microscope.

Xenograft experiments and IHC

All experimental procedures and animal care protocols were approved by the Animal Care Committee of Southeast University. Athymic nude mice (4-week-old, male) were randomly divided into three groups (n = 4/group) and treated with different concentrations of anlotinib (0, 3, and 6 mg/kg). Transfected U87MG-Luc cells (500,000 cells in 3 μL Hanks/mouse) were implanted stereotactically, anterior (1.0 mm) and lateral (2.5 mm) to the bregma and at depth of 3.5 mm from the skull surface [19]. Luciferin (150 mg/kg) was injected into mice intraperitoneally, and the Caliper IVIS Spectrum was used for in vivo bioluminescence imaging. Nude mice were killed after 28 days, and tumor tissues were prepared for western blotting and IHC. IHC staining was conducted according to methods previously described [20].

Statistical analysis

The SPSS version 25.0 (IBM Corporation, Armonk, NY, USA) software was used to analyze all data. Data were expressed as mean ± standard error of the mean (SEM) and the differences between control and treatment groups were evaluated by Student’s t-test. Statistical comparisons among three or more groups were performed using an analysis of variance (ANOVA) with Tukey’s post hoc test. A p value < 0.05 was considered statistically significant.

Results

Anlotinib suppressed the proliferation of glioblastoma cells

To examine the anti-proliferative effects of anlotinib on glioblastoma cells, the CCK-8 assay was used to assess cell viability. Cells were treated with anlotinib (0, 1.25, 2.5, 5, 10, and 20 μM) for 24, 48, or 72 h, and 0.1% DMSO served as the vehicle control. The results revealed that anlotinib was able to induce cell death in both a concentration and time-dependent manner in all glioblastoma cell lines tested (Fig. 1a–c). The colony-formation assay was used to test long-term effects of anlotinib on cell proliferation. As shown in Fig. 1d, the size of independent colonies was much smaller in the anlotinib-treated group than the vehicle-treated group, and the number of colonies was significantly reduced in the anlotinib-treated group. These results suggested that anlotinib inhibited the proliferation of glioblastoma cells in a dose-dependent manner.
Anlotinib inhibits migration and invasion of glioblastoma cells

First, wound healing was used to access the migratory ability of glioblastoma cells (A172, U87, and U251). Anlotinib decreased the migratory ability of glioblastoma cells compared to untreated control cells (Fig. 2a, b). Subsequently, Transwell migration and Matrigel invasion assays were performed, which revealed that the capacity of glioblastoma cells to migrate and invade were clearly reduced when the cells were pretreated with anlotinib compared to the vehicle-treated group (Fig. 2c–f). Taken together, these
Fig. 2 Anlotinib suppresses the migration and invasion capacity of glioblastoma cells in vitro. A172, U251 and U87 cells were treated with vehicle or anlotinib for 24 h. Cells that migrated into the wounded areas were observed and imaged. b Quantification of the wound-healing ability. c, e The migration and invasion of glioblastoma cells in Transwell migration and Matrigel invasion assays were inhibited. d, f Quantification of the number of migrated and invasive cells was analyzed from five independent fields of view. The wound-healing ability of the vehicle-treated group was adjusted to the value of 100. Values are expressed as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 versus the control.
Fig. 3 Anlotinib induces G2/M phase cell cycle arrest, induces apoptosis, mediates expression of apoptosis-related proteins, and triggers autophagy in glioblastoma cells. 

**A** U87 cells were tested in after anlotinib treatment for 24 h by flow cytometry and arrested at the G2/M phases. 

**B** Anlotinib enhanced the ratio of apoptotic cells in a dose-dependent manner. 

**C** Anlotinib upregulated the levels of pro-apoptotic proteins (BAX and cleaved caspase-3). In addition, anlotinib downregulated the level of the anti-apoptotic protein Bcl-2. The cells were pretreated with anlotinib for 24 h. 

**D** Anlotinib reduced the expression levels of Beclin-1 and LC3B as detected by western blotting. 

**E** Immuno-fluorescence staining of LC3B showed that anlotinib increased autophagosome formation, and this process was suppressed by an inhibitor of autophagy (3-MA). Data are represented as mean ± SEM of four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 vs control group.
results demonstrated that anlotinib suppressed the migration and invasion of glioblastoma cells in a concentration-dependent manner.

**Anlotinib induces G2/M phase arrest**

To evaluate the effect of anlotinib treatment on the cell cycle profile, flow cytometry was used to analyze the cell cycle distribution of glioblastoma cells after pretreatment with 0, 2 and 4 μM of anlotinib for 24 h. In U87 cells treated with different concentrations of anlotinib, the percentage of cells in the G2/M phase increased in a dose-dependent manner (Fig. 3a, b). These data showed that anlotinib might contribute to cell cycle arrest of glioma cells in the G2/M phase.

**Anlotinib induces apoptosis and autophagy in glioblastoma cells**

Previous studies indicated that arresting the cell cycle initiates an apoptotic program [21, 22]. However, whether anlotinib has a pro-apoptotic effect is unknown. As such, the effect of anlotinib (0, 2, and 4 μM) treatment on apoptosis was examined. The percentage of apoptotic cells was elevated in three human glioblastoma cell lines (A172, U87, and U251) treated with anlotinib. The examination indicated that anlotinib was able to induce apoptosis when compared with the control group (Fig. 3c, d). Subsequently, western blotting was performed on apoptosis-related proteins (Bcl-2, BAX and caspase-3) to determine the mechanism of anlotinib-induced apoptosis. The results indicated that Bcl-2 was markedly upregulated, whereas the levels of cleaved-caspase-3 and BAX decreased with anlotinib compared to vehicle-treated cells (Fig. 3e, f).

It has been reported that excessive autophagy may serve as a cell death pathway [23]. Importantly, anlotinib was also observed to induce the expression of autophagy-related proteins (Beclin-1 and LC3B) according to western blotting (Fig. 3g, h). Further exploration using immunofluorescence showed that 3-MA could inhibit the formation of autophagosomes induced by anlotinib during the initial stages of autophagy (Fig. 3i).

Taken together, these results indicated that anlotinib initiated both apoptotic and autophagic programs in glioblastoma cell lines.

**Anlotinib inhibits tubular formation of HUVECs and glioblastoma through JAK2/STAT3/VEGFA pathway**

The JAK2/STAT3 signaling pathway plays a crucial role in angiogenesis [16, 17]. In addition, anlotinib has been shown to target VEGFR [11]. VEGFA is a downstream target gene of JAK2/STAT3 signaling and promotes angiogenesis [24, 25].

To evaluate the effects of anlotinib on the sprouting of new capillaries, a tubular formation assay was performed. Briefly, HUVECs were seeded on the surface of Matrigel and treated with supernatant collected from the tumor cell lines. The human umbilical endothelial tubular formation was inhibited by U87/anlotinib (2 μM) supernatant, which was enhanced by S3I-201 (STAT3 inhibitor, 100 μM; Fig. 4a, b). One previous study suggests that VEGF and its receptors facilitate tumor angiogenesis, but low levels of VEGFA could suppress this process; VEGFA was considered to play a leading role in tumor angiogenesis [26]. Therefore, VEGFA concentration was detected in the tumor supernatant by ELISA. Importantly, treatment with anlotinib and/or S3I-201 was able to decrease the levels of VEGFA secreted by U87 cells (Fig. 4c). To further explore the underlying molecular mechanisms in glioblastoma cells treatment with anlotinib, the expression of many signaling proteins (p-JAK2, STAT3, p-STAT3, VEGFA, cyclin A2, cyclin D1, HMGB1, and MMP2) were determined in all three cell types by western blotting. The results showed that the JAK2/STAT3/VEGFA pathway components were reduced in a concentration-dependent manner after anlotinib (0, 2, and 4 μM) treatment (Fig. 4d–f). Furthermore, the JAK2/STAT3/VEGFA pathway components, the expression of cell motility-related proteins (HMGB1 and MMP2), and proliferation-related proteins (cyclin A2 and cyclin D1) were decreased after anlotinib (2 μM) treatment, an effect that was enhanced by S3I-201 (100 μM; Fig. 4g, h).

Collectively, the above findings demonstrated that the anti-angiogenic and anti-glioblastoma effects of anlotinib may be due to its influence on the JAK2/STAT3/VEGFA signaling pathway.

**The combination of anlotinib and TMZ enhances the anti-glioblastoma effects**

First, the viability of cell treated with anlotinib (2 μM) and/or TMZ (100 μM) was assessed with a CCK-8 assay. U87 and U251 cells were treated with anlotinib and/or TMZ for 48 h, and 0.1% DMSO was used as the vehicle control. The data suggested a synergistic effect when cells were treated with both anlotinib and TMZ (Fig. 5a).

A wound-healing assay was used to access the migratory ability of glioma cells treated with anlotinib or TMZ alone, or in combination. Figure 5b, c revealed that the combination of the drugs greatly increased the inhibition of cell migration compared to each drug used alone.

To investigate whether the enhanced cytotoxicity was due to cellular apoptosis, the pro-apoptotic effects of the combination treatment was assessed by flow cytometry in
all three cell lines treated with anlotinib and/or TMZ. The data revealed that there were significant differences between anlotinib or TMZ single treatment groups and the combination group. Anlotinib or TMZ treatment alone increased apoptosis compared to the control, but the drugs in combination increased apoptosis more effectively than either drug alone (Fig. 5d, e).
To explore whether anlotinib and TMZ have a cooperative anti-angiogenic effect, the changes to components of the JAK2/STAT3/VEGFA signaling pathway were assessed following single treatments or a combination treatment. It was found that the combination of the drugs was more effective than a single dose of either agent to suppress JAK2/STAT3/VEGFA signaling (Fig. 5f, g).
Fig. 6 Anlotinib restraints GBM growth in vivo. a Representative bioluminescent images showed tumor volumes in orthotopic GBM model at 7, 14 and 28 days. b Quantification of tumor volumes in the different treatment arms. c Representative images of IHC staining of Ki-67. d Tumor tissues from two different nude mice in each treatment group were analyzed by western blotting. The relative tumor volumes of the control group were adjusted to the value of 1. Data were represented as means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 vs control group.
Taken together, these results suggested that anlotinib and TMZ had a cooperative anti-glioblastoma effect.

**Anlotinib restraints GBM growth in vivo**

Although anlotinib markedly suppressed the growth of human glioma cells in vitro, the anti-glioblastoma effect of anlotinib remains unknown in vivo. Therefore, an orthotopic GBM model in nude mice was used to determine the effect of anlotinib in vivo. In vivo bioluminescence imaging of the mice every 7 days was performed. The results suggested that anlotinib delayed tumor growth in comparison with the control group (Fig. 6a, b). IHC staining also found that anlotinib reduced the positivity of the proliferation index Ki-67 (Fig. 6c). In addition, supporting the in vitro data, western blotting revealed that anlotinib reduced the expression of p-JAK2, p-STAT3, and VEGFA in vivo (Fig. 6d). Taken together, anlotinib was shown to inhibit GBM proliferation in vivo.

**Discussion**

GBM are fatal brain tumors characterized by highly invasive cells with extremely strong vascular proliferation capabilities among solid tumors. Angiogenesis is a hallmark feature of GBM and the role of anti-angiogenic agents in GBM treatment has received increased attention. Bevacizumab (Bev), an anti-VEGF monoclonal antibody, was confirmed to suppress GBM growth in vivo [27] as well as the angiogenesis-promoting effects of glioma cells [28]. However, patients treated with Bev suffered from adverse effects that ultimately reduced their quality of life. Due to other treatment options lacking efficacy, Bev has been classified as a second-line drug for newly diagnosed GBM patients [29]. Therefore, novel and effective anticancer drugs with minimal adverse effects are urgently required to help these patients.

Anlotinib, a novel multi-targeted tyrosine kinase inhibitor, has been shown to inhibit VEGFR and has antitumor effects in many types of cancer. Anlotinib suppressed hepatocellular carcinoma via ERK and Akt signaling [13], and the dual blockade of VEGFR2 and mesenchymal–epithelial transition factor (MET) played an important role in the anlotinib-mediated inhibition of osteosarcomas [14]. With anlotinib treatment, intrahepatic cholangiocarcinoma was inhibited by blocking the VEGFR2/phosphoinositide 3-kinase (PI3K)/Akt cascade. Other cancers shown to be inhibited by anlotinib have included soft tissue sarcoma [30], esophageal squamous cell carcinoma [31], and gastric cancer [32]. Interestingly, the mechanism of anlotinib appears to be different compared to more commonly used anti-angiogenesis drugs. It not only acts on endothelial cells, perivascular cells, and smooth muscle cells by targeting VEGFRs, fibroblast growth factor receptors and platelet-derived growth factor receptors, but anlotinib can also act directly on tumor cells by targeting c-kit [33]. In clinical applications, anlotinib had been administered in a phase II clinical trial for non-small cell lung cancer patients to evaluate its therapeutic efficacy and safety [34]. Anlotinib is also being assessed in a recent single-center, single-arm, phase II trial that encompasses many cancer types including osteosarcoma, prostate cancer, chondrosarcoma, kidney cancer, gastrointestinal stromal tumor, pulmonary sarcomatoid carcinoma as well as 20 other types of cancer [35]. Therefore, the current study aimed to demonstrate whether (and how) anlotinib could be beneficial to treat glioblastomas.

In this study, the anti-glioblastoma effect of anlotinib in vitro was supported by results from three glioblastoma cell lines. Compared with canonical anti-glioma drugs, anlotinib was administrated at a lower dose and showed a more pronounced effect. In vitro, anlotinib inhibited the migratory and invasive capacities of glioblastoma cells, and arrested the cell cycle in the G2/M phase, which ultimately lead to cytotoxic effects on the glioma cell lines in a dose-dependent manner. The upregulation of BAX and downregulation of Bcl-2 were involved in caspase-3 activation following anlotinib treatment, resulting in increased rates of apoptosis. Although the difference in the proportion of apoptotic rates was statistically significant, the apoptotic rate obtained by flow cytometry was not as pronounced as the increased expression of pro-apoptotic proteins. There are three possible reasons for this slight discrepancy. First, exorbitant autophagy can promote cell death (type 2 cell death), which differs from apoptosis (type 1 cell death) according to the morphological status [36]. In this study, anlotinib also increased the expression of LC3B, which lead to excessive autophagy. Thus, anlotinib possibly activate type 2 cell death rather than apoptosis. Second, in regulated cell death, pyroptosis has gained increasing attention, and crosstalk between pyroptosis and apoptosis has been reported [37–39]. It is possible that the elevation of caspase-3 promoted pyroptosis rather than apoptosis. Third, autophagy can protect malignant cells against harsh microenvironmental conditions to enhance tumor progression [36, 40]. However, the ultimate goal of apoptosis is cellular death. Accordingly, with protection from autophagy, the final proportion of apoptosis may not appear as high as expected, despite the drastic changes in the levels of apoptosis-related proteins.

Although TMZ is a first-line chemotherapy agent against GBM in the clinic, it comes with a multitude of challenges. The response to TMZ is variable among patients [41], and resistance can occur rapidly after TMZ treatment [42]. The presence of TMZ resistance contributes to the poor prognosis and has researchers and clinicians concerned [41]. Thus, combination treatment methods have been given
consideration. Gossypol was used in combination with TMZ for the inhibition of glioma cells in vitro and in female BALB/c nu/nu mice [43]. In the current study, it was also found that anlotinib can mediate the JAK2/STAT3/VEGFA signaling pathway in glioma cells to decrease levels of secretory VEGFA and angiogenesis, and in combination with TMZ, the anti-angiogenesis and cytotoxic effects of anlotinib are improved. Furthermore, it was shown that anlotinib also reduced the growth rate of glioma cells and suppressed the JAK2/STAT3/VEGFA signaling pathway in vivo.

In summary, the current findings suggested that anlotinib can suppress the proliferation, migration, invasion, and angiogenesis ability of glioblastoma cells in a dose-dependent manner, and the cooperative effect of anlotinib with TMZ contributes to further enhanced cytotoxicity and anti-angiogenesis in human glioblastoma cells. This strong evidence proves that anlotinib is a promising therapeutic agent for the treatment of glioblastoma.

Author contributions PX performed the study and wrote the paper; HW and HP designed the study and provided the funding. JC and CD revised the paper.

Funding This work was supported by Grants from The Science Foundation of Jiangsu Province, China: Grant numbers ZDXKB2016023 (HD Wang).

Declarations

Conflict of interest The authors report no conflicts of interest in this work.

Ethical approval The study was approved by the animal ethical committee of Southeast University (Jiangsu, China).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ostrom QT, Gittleman H, Kruchko C, Barnholtz-Sloan JS (2019) Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival. J Neurooncol 142(1):27–38. https://doi.org/10.1007/s11060-018-03073-z

2. Wang Y, Liang D, Chen J, Chen H, Fan R, Gao Y, Gao Y, Tao R, Zhang H (2021) Targeted therapy with anlotinib for a patient with an oncogenic FGFR3-TACC3 fusion and recurrent glioblastoma. Oncologist 26(3):173–177. https://doi.org/10.1007/10633-013-0053-7

3. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, German Glioma N (2007) Long-term survival with glioblastoma multiforme. Brain 130(Pt 10):2596–2606. https://doi.org/10.1093/brain/awm204

4. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmoud U, Chmura SJ, Weichselbaum RR, McCarthy BJ (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107:207–212. https://doi.org/10.1007/s11060-011-0738-7

5. Jarzabek MA, Sweeney KJ, Evans RL, Jacobs AH, Stupp R, O’Brien D, Berger MS, Prenh JH, Byrne AT (2013) Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. Drug Discov Today 18(21–22):1052–1066. https://doi.org/10.1016/j.drudis.2013.06.004

6. Sharma A, Bendre A, Mondal A, Muzumdar D, Goel N, Shiras A (2017) Angiogenic gene signature derived from subtype specific cell models segregate proneural and mesenchymal glioblastoma. Front Oncol 7:146. https://doi.org/10.3389/fonc.2017.00146

7. Nam DH, Park K, Suh YL, Kim JH (2004) Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 11(4):863–869

8. Takano S, Yoshi Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Can Res 56(9):2185–2190

9. Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y (2016) Safety, pharmacodynamics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 9(1):105. https://doi.org/10.1186/s13045-016-0332-8

10. Lin B, Song X, Yang D, Bai D, Yao L, Niu A (2018) Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFFR1. Gene 654:77–86. https://doi.org/10.1016/j.gene.2018.02.026

11. Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, Wang L, Xia Y, Qiao Y, Sun W, Fei J, Chen T, Zhao F, Yang B, Jiang X (2019) Autophagy inhibition potentiates the anti-angiogenic property of multikinease inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res 38(1):71. https://doi.org/10.1186/s13046-019-1093-3

12. Li H, Liu Y, Liu X, Zhao D, Liu J, Cheng Y (2020) A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer. Anticancer Drugs 31(10):1057–1064. https://doi.org/10.1097/CAD.0000000000000969

13. He C, Wu T, Hao Y (2018) Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Biophys Res Commun 503(4):3093–3099. https://doi.org/10.1016/j.bbrc.2018.08.098

14. Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, Mao M, Zuo D, Zhou Z, Wang C, Fu Z, Wang Z, Duan Z, Hua Y, Cai Z (2019) Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer 145(4):979–993. https://doi.org/10.1002/ijc.32180

15. Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109(4):1207–1219. https://doi.org/10.1111/cas.13536
16. Huynh J, Etemadi N, Holland F, Ernst M, Buchert M (2017) The JAK/STAT3 axis: a comprehensive drug target for solid malignancies. Semin Cancer Biol 45:13–22. https://doi.org/10.1016/j.semcancer.2017.06.001

17. Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14(11):736–746. https://doi.org/10.1038/nrc3818

18. Zhu Y, Fang J, Wang H, Fei M, Tang T, Liu K, Niu W, Zhou Y (2018) Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca2(+)-dependent pathway. Drug Des Dev Ther 12:3247–3261. https://doi.org/10.2147/DDDT.S176403

19. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF (2000) An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 92(2):326–333. https://doi.org/10.3171/jns.2000.92.2.0326

20. Zhou Y, Dai W, Wang H, Pan H, Wang Q (2018) Long non-coding RNA CASP5 promotes the malignant phenotypes of human glioblastoma multiforme. Biochem Biophys Res Commun 500(4):966–972. https://doi.org/10.1016/j.bbrc.2018.04.217

21. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23(16):2825–2837. https://doi.org/10.1038/sj.onc.1207528

22. Lo HL, Nakajima S, Ma L, Walter B, Yasui A, Ethell DW, Owen LB (2005) Differential biologic effects of CPD and 6-4PP UV-induced DNA damage on the induction of apoptosis and cell-cycle arrest. BMC Cancer 5:135. https://doi.org/10.1186/1471-2407-5-135

23. Tsai HC, Tzeng HE, Huang CY, Huang YL, Tsai CH, Wang SW, Wang PC, Chang AC, Fong YC, Tang CH (2017) WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma. Cell Death Dis 8(4):e2750. https://doi.org/10.1038/s41302-016-2187-3

24. Carbayo-Pescador S, Ordonez R, Benet M, Jover R, Garcia-Palomo A, Mauriz JL, Gonzalez-Gallego J (2013) Inhibition of VEGF expression through blockade of Hifalpha and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer 109(1):83–91. https://doi.org/10.1038/bjc.2013.285

25. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027. https://doi.org/10.1200/JCO.2005.06.081

26. Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB, Welch WC (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55(2):91–100. https://doi.org/10.1023/A:1013329832067

27. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843–7848. https://doi.org/10.1158/0008-5472.CAN-06-1010

28. Schaub C, Schafer N, Mack F, Stuplchik M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M (2016) The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma. J Cancer Res Clin Oncol 142(8):1825–1829. https://doi.org/10.1007/s00432-016-2187-3

29. Li S (2021) Anlotinib: a novel targeted drug for bone and soft tissue sarcoma. Front Oncol 11:664853. https://doi.org/10.3389/fonc.2021.664853

30. Shi J, Zhang Y, Wang J, Li J, Li Z (2020) Anlotinib combined with chemoradiotherapy exhibits significant therapeutic efficacy in esophageal squamous cell carcinoma. Front Oncol 10:995. https://doi.org/10.3389/fonc.2020.00995

31. Wang J, Wu DX, Meng L, Ji G (2020) Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil potassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-arm and single-centred clinical trial. BMJ Open 10(6):e034685. https://doi.org/10.1136/bmjopen-2019-034685

32. Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11(1):120. https://doi.org/10.1186/s13045-018-0664-7

33. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y (2018) Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 4(11):1569–1575. https://doi.org/10.1001/jamaoncol.2018.3039

34. Ryskbein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L (2018) The autophagic network and cancer. Nat Cell Biol 20(3):243–251. https://doi.org/10.1038/s41556-018-0042-2

35. McKenzie BA, Dixit VM, Power C (2020) Fiery Cell Death: Pyroptosis in the Central Nervous System. Trends Neurosci 43(1):55–73. https://doi.org/10.1016/j.tins.2019.11.005

36. Wang Y, Yin B, Li D, Wang G, Han X, Sun X (2018) GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. Biochem Biophys Res Commun 495(1):1418–1425. https://doi.org/10.1016/j.bbrc.2017.11.156

37. Hu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y, Li W, Wang J, Zhao X, Yu Z, Ma P, Zhuang G (2018) Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death. Clin Cancer Res 24(23):6606–6677. https://doi.org/10.1158/1078-0432.CCR-18-1478

38. Santana-Codina N, Mancias JD, Kimmelman AC (2017) The role of autophagy in cancer. Annu Rev Cancer Biol 1:19–39. https://doi.org/10.1146/annurev-cancerbio-041816-122338

39. Kim SS, Raite A, Kim E, PiroilloKF, Chang EH (2015) A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine 11(2):301–311. https://doi.org/10.1016/j.nano.2014.09.005

40. Ge X, Pan MH, Wang L, Li W, Jiang C, He J, Abouzid K, Liu LZ, Shi Z, Jiang BH (2018) Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bak axis. Cell Death Dis 9(11):1128. https://doi.org/10.1038/s41419-018-1176-7

41. Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT (2014) Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. Br J Cancer 111(12):2275–2286. https://doi.org/10.1038/bjc.2014.529  

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.